US 12,077,578 B2
Compositions and methods for treating synucleinopathies
Josefine Nielsen Søderberg, Valby (DK); Pekka Kallunki, Valby (DK); Louise Buur, Valby (DK); and Frank Larsen, Valby (DK)
Assigned to H. Lundbeck A/S, Valby (DK)
Filed by H. Lundbeck A/S, Valby (DK)
Filed on Jun. 26, 2023, as Appl. No. 18/341,437.
Application 18/341,437 is a continuation of application No. PCT/EP2022/075402, filed on Sep. 13, 2022.
Claims priority of application No. 21197120 (EP), filed on Sep. 16, 2021.
Prior Publication US 2024/0025979 A1, Jan. 25, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/39591 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 2039/545 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering to the patient a full length monoclonal antibody which binds to alpha synuclein at a dose of 200 mg once every 4 weeks, wherein the antibody comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 34, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.